Arc Raiders developer Embark Studios recently introduced a mysterious map modifier to the extraction shooter, and players are ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no ...

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in ...

New information emerges that suggests Embark Studios may be gearing up to release new ARC Raiders content much sooner than ...

ARC Raiders developer Embark says it is working on multiple new maps for its hit extraction shooter, as the studio finally ...

That "Enemy Forces" bit is important, since it stops some sweatily-optimised, out-of-bounds-jumping, breakneck route from ...

Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.

If you want to add a bit of dimension to your old fashioned or margarita, consider adding a splash of this bubbly booze. Here ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Dungeons & Dragons' bloody handed new subclass is part Bhaalspawn, part Dark Urge, all teleporting terror - here's how to ...

Banning things doesn’t mean that the forbidden thing goes away. The prime minister should realise that by now.

Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for ...